bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S8 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Authors: Beinat Corinne , Patel Chirag B. , Haywood Tom , Murty Surya , Naya Lewis , Castillo Jessa B. , Reyes Samantha T. , Phillips Megan , Buccino Pablo , Shen Bin , Park Jun Hyung , Koran Mary Ellen I. , Alam Israt S. , James Michelle L. , Holley Dawn , Halbert Kim , Gandhi Harsh , He Joy Q. , Granucci Monica , Johnson Eli , Liu Daniel Dan , Uchida Nobuko , Sinha Rahul , Chu Pauline , Born Donald E. , Warnock Geoffrey I. , Weissman Irving , Hayden-Gephart Melanie , Khalighi Mehdi , Massoud Tarik F. , Iagaru Andrei , Davidzon Guido , Thomas Reena , Nagpal Seema , Recht Lawrence D. , Gambhir Sanjiv Sam
Published: April 2023

Imaging of IC-2
Supplementary Figure S5 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Authors: Beinat Corinne , Patel Chirag B. , Haywood Tom , Murty Surya , Naya Lewis , Castillo Jessa B. , Reyes Samantha T. , Phillips Megan , Buccino Pablo , Shen Bin , Park Jun Hyung , Koran Mary Ellen I. , Alam Israt S. , James Michelle L. , Holley Dawn , Halbert Kim , Gandhi Harsh , He Joy Q. , Granucci Monica , Johnson Eli , Liu Daniel Dan , Uchida Nobuko , Sinha Rahul , Chu Pauline , Born Donald E. , Warnock Geoffrey I. , Weissman Irving , Hayden-Gephart Melanie , Khalighi Mehdi , Massoud Tarik F. , Iagaru Andrei , Davidzon Guido , Thomas Reena , Nagpal Seema , Recht Lawrence D. , Gambhir Sanjiv Sam
Published: April 2023

Post-therapy Imaging of IC-1
Supplementary Table S1 from High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
Authors: Sánchez-Guixé Mònica , Hierro Cinta , Jiménez José , Viaplana Cristina , Villacampa Guillermo , Monelli Erika , Brasó-Maristany Fara , Ogbah Zighereda , Parés Mireia , Guzmán Marta , Grueso Judit , Rodríguez Olga , Oliveira Mafalda , Azaro Analía , Garralda Elena , Tabernero Josep , Casanovas Oriol , Scaltriti Maurizio , Prat Aleix , Dienstmann Rodrigo , Nuciforo Paolo , Saura Cristina , Graupera Mariona , Vivancos Ana , Rodon Jordi , Serra Violeta
Published: April 2023

Supplementary Table S1 PDXs subtype, genotype and drug efficacy data
Figure S4 from High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
Authors: Sánchez-Guixé Mònica , Hierro Cinta , Jiménez José , Viaplana Cristina , Villacampa Guillermo , Monelli Erika , Brasó-Maristany Fara , Ogbah Zighereda , Parés Mireia , Guzmán Marta , Grueso Judit , Rodríguez Olga , Oliveira Mafalda , Azaro Analía , Garralda Elena , Tabernero Josep , Casanovas Oriol , Scaltriti Maurizio , Prat Aleix , Dienstmann Rodrigo , Nuciforo Paolo , Saura Cristina , Graupera Mariona , Vivancos Ana , Rodon Jordi , Serra Violeta
Published: April 2023

Supplementary Figure 4. Impact of FGF ligand blockade in FGFRi treatment response. A) Analysis of mRNA expression levels of FGF ligands by HTG. FGFR1-4 and FGF3/4/19 CN and mRNA status are depicted in the box underneath. Gene expression levels are expressed from the lowest -grey- to the 90th percentile of expression -red-; samples above the 90th percentile are highlighted with stripes. B) Ex vivo analysis of Rogaratinib response (IC50) in 5 PDC models (PDX-derived cell cultures), with or without co-treatment with an FGF-trap (NSC12). The relative mRNA expression levels of relevant FGF ligands and FGFR2 in each model, and the corresponding FGFRi response is summarized in the panel underneath. Statistical analysis: Sidak's multiple comparisons test.
Figure S4 from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma
Authors: Angeles Christina V. , Velez Ana , Rios Jordan , Laxa Bernadette , Shum David , Ruiz Penelope D. , Shen Yawei , Ostrovnaya Irina , Gularte-Mérida Rodrigo , Nacev Benjamin A. , Dickson Mark A. , Djaballah Hakim , Okada Tomoyo , Singer Samuel
Published: April 2023

Irinotecan does not cause gross toxicity and induces C/EBPÎ± expression in DDLS tumors in vivo, while doxorubicin leads to weight loss.
Figure S3 from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma
Authors: Angeles Christina V. , Velez Ana , Rios Jordan , Laxa Bernadette , Shum David , Ruiz Penelope D. , Shen Yawei , Ostrovnaya Irina , Gularte-Mérida Rodrigo , Nacev Benjamin A. , Dickson Mark A. , Djaballah Hakim , Okada Tomoyo , Singer Samuel
Published: April 2023

SN-38/irinotecan suppresses HIF1ï�¡ expression in vitro and in vivo.
Supplementary Data from Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer
Authors: Fasching Peter A. , Liu Duan , Scully Steve , Ingle James N. , Lyra Paulo C. , Rack Brigitte , Hein Alexander , Ekici Arif B. , Reis Andre , Schneeweiss Andreas , Tesch Hans , Fehm Tanja N. , Heinrich Georg , Beckmann Matthias W. , Ruebner Matthias , Huebner Hanna , Lambrechts Diether , Madden Ebony , Shen Jess , Romm Jane , Doheny Kim , Jenkins Gregory D. , Carlson Erin E. , Li Liang , Fridley Brooke L. , Cunningham Julie M. , Janni Wolfgang , Monteiro Alvaro N.A. , Schaid Daniel J. , Häberle Lothar , Weinshilboum Richard M. , Wang Liewei
Published: April 2023

Supplementary Data from Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer
Supplementary Figures from Development and Multiple Validation of the Protein Multi-marker Panel for Diagnosis of Pancreatic Cancer
Authors: Kim Yoseop , Yeo Injoon , Huh Iksoo , Kim Jaenyeon , Han Dohyun , Jang Jin-Young , Kim Youngsoo
Published: April 2023

Supplementary Figures 1-5.
Supplementary Table 4 from Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies
Authors: Liang Yi , Jeganathan Sujeeve , Marastoni Stefano , Sharp Adam , Figueiredo Ines , Marcellus Richard , Mawson Amanda , Shalev Zvi , Pesic Aleksandra , Sweet Joan , Guo Haiyang , Uehling David , Gurel Bora , Neeb Antje , He Housheng Hansen , Montgomery Bruce , Koritzinsky Marianne , Oakes Samantha , de Bono Johann S. , Gleave Martin , Zoubeidi Amina , Wouters Bradly G. , Joshua Anthony M.
Published: April 2023

Clinical characteristics of prostate cancer patients with matched diagnostic (archival) castration-sensitive and metastatic castration-resistant tissue biopsies
Supplementary Data from Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
Authors: Dziadziuszko Rafal , Peters Solange , Mok Tony , Camidge D. Ross , Gadgeel Shirish M. , Ou Sai-Hong Ignatius , Konopa Krzysztof , Noé Johannes , Nowicka Malgorzata , Bordogna Walter , Morcos Peter N. , Smoljanovic Vlatka , Shaw Alice T.
Published: April 2023

Supplementary Data from Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
Supplementary Fig. S6 from Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies
Authors: Liang Yi , Jeganathan Sujeeve , Marastoni Stefano , Sharp Adam , Figueiredo Ines , Marcellus Richard , Mawson Amanda , Shalev Zvi , Pesic Aleksandra , Sweet Joan , Guo Haiyang , Uehling David , Gurel Bora , Neeb Antje , He Housheng Hansen , Montgomery Bruce , Koritzinsky Marianne , Oakes Samantha , de Bono Johann S. , Gleave Martin , Zoubeidi Amina , Wouters Bradly G. , Joshua Anthony M.
Published: April 2023

16DCRPC cell line variants expressing BCL-2 and IKKB are resistant to ENZ
Supplementary Data from Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)
Authors: Nixon Andrew B. , Halabi Susan , Liu Yingmiao , Starr Mark D. , Brady John C. , Shterev Ivo , Luo Bin , Hurwitz Herbert I. , Febbo Phillip G. , Rini Brian I. , Beltran Himisha , Small Eric J. , Morris Michael J. , George Daniel J.
Published: April 2023

Supplementary Data from Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)
Supplementary Figure from A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
Authors: de Kouchkovsky Ivan , Rao Arpit , Carneiro Benedito A. , Zhang Li , Lewis Catriona , Phone Audrey , Small Eric J. , Friedlander Terence , Fong Lawrence , Paris Pamela L. , Ryan Charles J. , Szmulewitz Russell Z. , Aggarwal Rahul
Published: April 2023

Supplementary Figure from A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
Supplementary Table S2 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
Authors: Obradovic Aleksandar , Graves Diana , Korrer Michael , Wang Yu , Roy Sohini , Naveed Abdullah , Xu Yaomin , Luginbuhl Adam , Curry Joseph , Gibson Michael , Idrees Kamran , Hurley Paula , Jiang Peng , Liu X. Shirley , Uppaluri Ravindra , Drake Charles G. , Califano Andrea , Kim Young J.
Published: April 2023

Supplementary Table S2 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
Supplementary Data from A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
Authors: Choudhury Atish D. , Higano Celestia S. , de Bono Johann S. , Cook Natalie , Rathkopf Dana E. , Wisinski Kari B. , Martin-Liberal Juan , Linch Mark , Heath Elisabeth I. , Baird Richard D. , García-Carbacho Javier , Quintela-Fandino Miguel , Barry Simon T. , de Bruin Elza C. , Colebrook Steve , Hawkins George , Klinowska Teresa , Maroj Brijesh , Moorthy Ganesh , Mortimer Peter G. , Moschetta Michele , Nikolaou Myria , Sainsbury Liz , Shapiro Geoffrey I. , Siu Lillian L. , Hansen Aaron R.
Published: April 2023

Supplementary Data from A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
Supplementary Figure S5 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
Authors: Obradovic Aleksandar , Graves Diana , Korrer Michael , Wang Yu , Roy Sohini , Naveed Abdullah , Xu Yaomin , Luginbuhl Adam , Curry Joseph , Gibson Michael , Idrees Kamran , Hurley Paula , Jiang Peng , Liu X. Shirley , Uppaluri Ravindra , Drake Charles G. , Califano Andrea , Kim Young J.
Published: April 2023

Supplementary Figure S5 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
Supplementary Figure S3 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
Authors: Obradovic Aleksandar , Graves Diana , Korrer Michael , Wang Yu , Roy Sohini , Naveed Abdullah , Xu Yaomin , Luginbuhl Adam , Curry Joseph , Gibson Michael , Idrees Kamran , Hurley Paula , Jiang Peng , Liu X. Shirley , Uppaluri Ravindra , Drake Charles G. , Califano Andrea , Kim Young J.
Published: April 2023

Supplementary Figure S3 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
Supplementary Figure S2 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
Authors: Obradovic Aleksandar , Graves Diana , Korrer Michael , Wang Yu , Roy Sohini , Naveed Abdullah , Xu Yaomin , Luginbuhl Adam , Curry Joseph , Gibson Michael , Idrees Kamran , Hurley Paula , Jiang Peng , Liu X. Shirley , Uppaluri Ravindra , Drake Charles G. , Califano Andrea , Kim Young J.
Published: April 2023

Supplementary Figure S2 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
Supplementary Data from Exposure–Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma
Authors: Hamuro Lora , Hu Zheyi , Passarell Julie , Barcomb Heather , Zhang Joshua , Goldstein Shay , Bello Akintunde , Roy Amit , Zhu Li
Published: April 2023

Supplementary Data from Exposure–Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma
Supplementary Figure from A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222
Authors: Moore Halle C.F. , Barlow William E. , Somlo George , Gralow Julie R. , Schott Anne F. , Hayes Daniel F. , Kuhn Peter , Hicks James B. , Welter Lisa , Dy Philip A. , Yeon Christina H. , Conlin Alison K. , Balcueva Ernie , Lew Danika L. , Tripathy Debasish , Pusztai Lajos , Hortobagyi Gabriel N.
Published: April 2023

Supplementary Figure from A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222
Supplementary Data from Anti-GD2 Antibodies Conjugated to IL15 and IL21 Mediate Potent Antitumor Cytotoxicity against Neuroblastoma
Authors: Nguyen Rosa , Zhang Xiyuan , Sun Ming , Abbas Shahroze , Seibert Charlie , Kelly Michael C. , Shern Jack F. , Thiele Carol J.
Published: April 2023

Supplementary Data from Anti-GD2 Antibodies Conjugated to IL15 and IL21 Mediate Potent Antitumor Cytotoxicity against Neuroblastoma
Supplementary Data from A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma
Authors: Saulnier-Sholler Giselle , Duda Dan G. , Bergendahl Genevieve , Ebb David , Snuderl Matija , Laetsch Theodore W. , Michlitsch Jennifer , Hanson Derek , Isakoff Michael S. , Bielamowicz Kevin , Kraveka Jacqueline M. , Ferguson William , Carmeliet Peter , De Deene A. , Gijsen Lore , Jain Rakesh K.
Published: April 2023

Supplementary Data from A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma
Supplementary Figure from Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Authors: Batra Vandana , Samanta Minu , Makvandi Mehran , Groff David , Martorano Paul , Elias Jimmy , Ranieri Pietro , Tsang Matthew , Hou Catherine , Li Yimei , Pawel Bruce , Martinez Daniel , Vaidyanathan Ganesan , Carlin Sean , Pryma Daniel A. , Maris John M.
Published: April 2023

Supplementary Figure from Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
Authors: Yonesaka Kimio , Tanizaki Junko , Maenishi Osamu , Haratani Koji , Kawakami Hisato , Tanaka Kaoru , Hayashi Hidetoshi , Sakai Kazuko , Chiba Yasutaka , Tsuya Asuka , Goto Hiroki , Otsuka Eri , Okida Hiroaki , Kobayashi Maki , Yoshimoto Ryoto , Funabashi Masanori , Hashimoto Yuuri , Hirotani Kenji , Kagari Takashi , Nishio Kazuto , Nakagawa Kazuhiko
Published: April 2023

Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
Supplementary Figure from Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer
Authors: Seeber Andreas , Battaglin Francesca , Zimmer Kai , Kocher Florian , Baca Yasmine , Xiu Joanne , Spizzo Gilbert , Novotny-Diermayr Veronica , Rieder Dietmar , Puccini Alberto , Swensen Jeff , Ellis Michelle , Goldberg Richard M. , Grothey Axel , Shields Anthony F. , Marshall John L. , Weinberg Benjamin A. , Sackstein Paul E. , Lim Kiat Hon , Tan Gek San , Nabhan Chadi , Korn W. Michael , Amann Arno , Trajanoski Zlatko , Berger Martin D. , Lou Emil , Wolf Dominik , Lenz Heinz-Josef
Published: April 2023

Supplementary Figure from Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer
Supplementary Table 2 from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Authors: Hall MacLean S. , Mullinax John E. , Cox Cheryl A. , Hall Amy M. , Beatty Matthew S. , Blauvelt Jamie , Innamarato Patrick , Nagle Luz , Branthoover Holly , Wiener Doris , Schachner Benjamin , Martinez Alberto J. , Richards Allison D. , Rich Carolyn J. , Colón Colón Marjorie , Schell Michael J. , Teer Jamie K. , Khushalani Nikhil I. , Weber Jeffrey S. , Mulé James J. , Sondak Vernon K. , Pilon-Thomas Shari , Sarnaik Amod A.
Published: April 2023

Supplementary Table 2 contains the Representativeness Table which demonstrates how this study fits into the larger patient population for metastatic melanoma.
Supplementary Methods Table 1 from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Authors: Hall MacLean S. , Mullinax John E. , Cox Cheryl A. , Hall Amy M. , Beatty Matthew S. , Blauvelt Jamie , Innamarato Patrick , Nagle Luz , Branthoover Holly , Wiener Doris , Schachner Benjamin , Martinez Alberto J. , Richards Allison D. , Rich Carolyn J. , Colón Colón Marjorie , Schell Michael J. , Teer Jamie K. , Khushalani Nikhil I. , Weber Jeffrey S. , Mulé James J. , Sondak Vernon K. , Pilon-Thomas Shari , Sarnaik Amod A.
Published: April 2023

The Supplementary Methods Table contains the antibodies and panels in support of the Flow Cytometry section of the Materials and Methods.
Supplementary Methods S1 from Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
Authors: Tantawy Shady I. , Sarkar Aloke , Hubner Stefan , Tan Zhi , Wierda William G. , Eldeib Abdelraouf , Zhang Shuxing , Kornblau Steven , Gandhi Varsha
Published: April 2023

Supplementary Methods
Supplementary Data from Acetylated HOXB13 Regulated Super Enhancer Genes Define Therapeutic Vulnerabilities of Castration-Resistant Prostate Cancer
Authors: Nguyen Duy T. , Yang Wei , Renganathan Arun , Weimholt Cody , Angappulige Duminduni H. , Nguyen Thanh , Sprung Robert W. , Andriole Gerald L. , Kim Eric H. , Mahajan Nupam P. , Mahajan Kiran
Published: April 2023

Supplementary Data from Acetylated HOXB13 Regulated Super Enhancer Genes Define Therapeutic Vulnerabilities of Castration-Resistant Prostate Cancer
Supplementary Figure from Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma
Authors: Meister Hanna , Look Thomas , Roth Patrick , Pascolo Steve , Sahin Ugur , Lee Sohyon , Hale Benjamin D. , Snijder Berend , Regli Luca , Ravi Vidhya M. , Heiland Dieter Henrik , Sentman Charles L. , Weller Michael , Weiss Tobias
Published: April 2023

Supplementary Figure from Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma
Supplementary Table from An Ex Vivo Organotypic Culture Platform for Functional Interrogation of Human Appendiceal Cancer Reveals a Prominent and Heterogenous Immunological Landscape
Authors: Weitz Jonathan , Hurtado de Mendoza Tatiana , Tiriac Herve , Lee James , Sun Siming , Garg Bharti , Patel Jay , Li Kevin , Baumgartner Joel , Kelly Kaitlin J. , Veerapong Jula , Hosseini Mojgan , Chen Yuan , Lowy Andrew M.
Published: April 2023

Supplementary Table from An Ex Vivo Organotypic Culture Platform for Functional Interrogation of Human Appendiceal Cancer Reveals a Prominent and Heterogenous Immunological Landscape
Supplementary Data from Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma
Authors: Meister Hanna , Look Thomas , Roth Patrick , Pascolo Steve , Sahin Ugur , Lee Sohyon , Hale Benjamin D. , Snijder Berend , Regli Luca , Ravi Vidhya M. , Heiland Dieter Henrik , Sentman Charles L. , Weller Michael , Weiss Tobias
Published: April 2023

Supplementary Data from Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma
Supplementary Figures S1-S5 from Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies
Authors: Zhai Yifan , Tang Qiuqiong , Fang Douglas D. , Deng Jing , Zhang Kaixiang , Wang Qixin , Yin Yan , Fu Chengcheng , Xue Sheng-Li , Li Na , Zhou Feng , Yang Dajun
Published: April 2023

Supplementary Figure 1. Synergistic antitumor activity of lisaftoclax combined with alrizomadlin in AML CDX mouse models.
Supplementary Figure 2. Mean plasma and tumor drug concentrations in a subcutaneous OCI-AML-3 CDX model in mice.
Supplementary Figure 3. Upregulation of P53 and BAX and downregulation of MCL-1 and BCL-xL by lisaftoclax combined with alrizomadlin in RS4;11cells expressing BCL-2G101V mutation.
Supplementary Figure 4. Characterization of RS4;11 cells expressing BCL-2 resistant mutants.
Supplementary Figure 5. Synergistic antiproliferative activity of combined treatment with lisaftoclax and alrizomadlin in parental RS4;11 cells, RS4;11 cells with WT BCL-2, and venetoclax-resistant RS4;11 cells expressing BCL-2 mutants.
Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
Authors: Ligon John A. , Sundby R. Taylor , Wedekind Mary F. , Arnaldez Fernanda I. , Del Rivero Jaydira , Wiener Lori , Srinivasan Ramaprasad , Spencer Melissa , Carbonell Amanda , Lei Haiyan , Shern John , Steinberg Seth M. , Figg William D. , Peer Cody J. , Zimmerman Sara , Moraly Josquin , Xu Xia , Fox Stephen , Chan King , Barbato Michael I. , Andresson Thorkell , Taylor Naomi , Pacak Karel , Killian J. Keith , Dombi Eva , Linehan W. Marston , Miettinen Markku , Piekarz Richard , Helman Lee J. , Meltzer Paul , Widemann Brigitte , Glod John
Published: April 2023

Differentially methylated regions with at least five CpGs, and a mean difference of greater than 20% between day 14 and baseline white blood cells
Table S2 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
Authors: Wang-Gillam Andrea , Lim Kian-Huat , McWilliams Robert , Suresh Rama , Lockhart Albert C. , Brown Amberly , Breden Marcus , Belle Jad I. , Herndon John , Bogner Savannah J. , Pedersen Katrina , Tan Benjamin , Boice Nicholas , Acharya Abhi , Abdiannia Mina , Gao Feng , Yoon Harry H. , Zhu Mojun , Trikalinos Nikolaos A. , Ratner Lee , Aranha Olivia , Hawkins William G. , Herzog Brett H. , DeNardo David G.
Published: April 2023

Supplemental Table 2
Patient demographics
Supplementary Figure from High-Dimensional and Spatial Analysis Reveals Immune Landscape–Dependent Progression in Cutaneous Squamous Cell Carcinoma
Authors: Ferguson Angela L. , Sharman Ashleigh R. , Allen Ruth O. , Ye Thomas , Lee Jenny H. , Low Tsu-Hui H. , Ch'ng Sydney , Palme Carsten E. , Ashford Bruce , Ranson Marie , Clark Jonathan R. , Patrick Ellis , Gupta Ruta , Palendira Umaimainthan
Published: April 2023

Supplementary Figure from High-Dimensional and Spatial Analysis Reveals Immune Landscape–Dependent Progression in Cutaneous Squamous Cell Carcinoma
Supplementary Table S4 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
Authors: Basile Giuseppe , Bandini Marco , Gibb Ewan A. , Ross Jeffrey S. , Raggi Daniele , Marandino Laura , Costa de Padua Tiago , Crupi Emanuele , Colombo Renzo , Colecchia Maurizio , Lucianò Roberta , Nocera Luigi , Moschini Marco , Briganti Alberto , Montorsi Francesco , Necchi Andrea
Published: April 2023

Distribution of the GSC subtypes according to the TCGA classification.
Supplementary Table S3 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
Authors: Basile Giuseppe , Bandini Marco , Gibb Ewan A. , Ross Jeffrey S. , Raggi Daniele , Marandino Laura , Costa de Padua Tiago , Crupi Emanuele , Colombo Renzo , Colecchia Maurizio , Lucianò Roberta , Nocera Luigi , Moschini Marco , Briganti Alberto , Montorsi Francesco , Necchi Andrea
Published: April 2023

Representativeness of study participants
Supplementary Figures S1-S4 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
Authors: Basile Giuseppe , Bandini Marco , Gibb Ewan A. , Ross Jeffrey S. , Raggi Daniele , Marandino Laura , Costa de Padua Tiago , Crupi Emanuele , Colombo Renzo , Colecchia Maurizio , Lucianò Roberta , Nocera Luigi , Moschini Marco , Briganti Alberto , Montorsi Francesco , Necchi Andrea
Published: April 2023

Supplementary Figure 1: Study flow-chart.
Supplementary Figure 2: Kaplan-Meier curves of event-free survival according to tertile-split tumor mutational burden.
Supplementary Figure 3. Kaplan-Meier curves of recurrence-free survival according to the molecular subtype.
Supplementary Figure 4: PD-L1 staining values (CPS percentages) according to molecular subtypes, split by the three subtyping classifiers GSC/Decipher, Consensus classification, and TCGA.
Supplemental Figure 5 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
Authors: Tsuji Junko , Li Tianyu , Grinshpun Albert , Coorens Tim , Russo Douglas , Anderson Leilani , Rees Rebecca , Nardone Agostina , Patterson Candace , Lennon Niall J. , Cibulskis Carrie , Leshchiner Ignaty , Tayob Nabihah , Tolaney Sara M. , Tung Nadine , McDonnell Donald P. , Krop Ian E. , Winer Eric P. , Stewart Chip , Getz Gad , Jeselsohn Rinath
Published: April 2023

Supplemental Figure 5: SSNVs detected in the cancer-related genes across 68 ctDNA WES
samples
Supplementary Data from MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma
Authors: Manning-Geist Beryl , Gordhandas Sushmita , Liu Ying L. , Zhou Qin , Iasonos Alexia , Da Cruz Paula Arnaud , Mandelker Diana , Roche Kara Long , Zivanovic Oliver , Maio Anna , Kemel Yelena , Chi Dennis S. , O'Cearbhaill Roisin E. , Aghajanian Carol , Weigelt Britta , Chui M. Herman , Grisham Rachel N.
Published: April 2023

Supplementary Data from MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma
Supplementary Data from Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets
Authors: Kocher Florian , Puccini Alberto , Untergasser Gerold , Martowicz Agnieszka , Zimmer Kai , Pircher Andreas , Baca Yasmine , Xiu Joanne , Haybaeck Johannes , Tymoszuk Piotr , Goldberg Richard M. , Petrillo Angelica , Shields Anthony F. , Salem Mohamed E. , Marshall John L. , Hall Michael , Korn W. Michael , Nabhan Chadi , Battaglin Francesca , Lenz Heinz-Josef , Lou Emil , Choo Su-Pin , Toh Chee-Keong , Gasteiger Silvia , Pichler Renate , Wolf Dominik , Seeber Andreas
Published: April 2023

Supplementary Data from Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets
Supplementary Figure S7 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect
Authors: Luo Ren , Onyshchenko Kateryna , Wang Liqun , Gaedicke Simone , Grosu Anca-Ligia , Firat Elke , Niedermann Gabriele
Published: April 2023

Expression and functional analyses of tumor cells cultured in vitro or analyzed ex vivo.
Supplementary Data File S1 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
Authors: Soni Upendra Kumar , Wang Yuhua , Pandey Ram Naresh , Roberts Ryan , Pressey Joseph G. , Hegde Rashmi S.
Published: April 2023

Western blots and quantifications
Supplementary Figure S5 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect
Authors: Luo Ren , Onyshchenko Kateryna , Wang Liqun , Gaedicke Simone , Grosu Anca-Ligia , Firat Elke , Niedermann Gabriele
Published: April 2023

Cisplatin induced ferroptosis without affecting ATP release, but not pyroptosis.
Supplementary Figure S4 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect
Authors: Luo Ren , Onyshchenko Kateryna , Wang Liqun , Gaedicke Simone , Grosu Anca-Ligia , Firat Elke , Niedermann Gabriele
Published: April 2023

Cell death and viability assays.
Supplementary Figure S2 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect
Authors: Luo Ren , Onyshchenko Kateryna , Wang Liqun , Gaedicke Simone , Grosu Anca-Ligia , Firat Elke , Niedermann Gabriele
Published: April 2023

Potency of platinum derivatives to facilitate the RT-induced abscopal effect in the C51 colon carcinoma model.
Supplementary Figure S11 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect
Authors: Luo Ren , Onyshchenko Kateryna , Wang Liqun , Gaedicke Simone , Grosu Anca-Ligia , Firat Elke , Niedermann Gabriele
Published: April 2023

Carboplatin induced Ifnb1, Cxcl10, as well as cytosolic mtDNA and gDNA in C51 cells in vitro.
Figure S4 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
Authors: Soni Upendra Kumar , Wang Yuhua , Pandey Ram Naresh , Roberts Ryan , Pressey Joseph G. , Hegde Rashmi S.
Published: April 2023

Characterization of Ewing sarcoma cell lines A673, RD-ES and SK-ESA.Western blot analysis of the IGF1R signaling pathway B. Western blot analysis of markers associated with the Replication Stress Response C. Western blot analysis of RPA phosphorylation and apoptosis measured by cleaved caspase 3 (CC3 levels).Cells stained with antibody towards IGF1R (red) and DAPI (blue) shows membranous staining in RD-ES and SK-ES cells, and very low levels in A673 cells.
Supplementary Figure S10 from Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect
Authors: Luo Ren , Onyshchenko Kateryna , Wang Liqun , Gaedicke Simone , Grosu Anca-Ligia , Firat Elke , Niedermann Gabriele
Published: April 2023

Graphical summary.
Figure S2 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
Authors: Soni Upendra Kumar , Wang Yuhua , Pandey Ram Naresh , Roberts Ryan , Pressey Joseph G. , Hegde Rashmi S.
Published: April 2023

Cell cycle analyses A. Dansylcadaverine-mediated nIGF1R depletion arrested CCH1 cells at the G1-phase and reduced the percentage of cells in the S-phase. B. Western blots show that Cyclin A2 and Cyclin D1 levels were high in CCH5 cells with nIGF1R relative to NCH6 with mIGF1R. C. Cell cycle analyses shows higher percentages of CCH1 and CCH5 cells in S-phase than CCH2 and NCH6 cells. D. CCH5 cells with nIGF1R divided faster, had higher percentages of S-phase cells with shorter S-phase duration than NCH6 with mIGF1R. E. EdU/BrdU double labelling-based S-phase duration analysis was carried out. Top panel shows that cells showed EdU-AF55+ and BrdU-FITC+ signals in comparison to unstained cells. F. Percentages of EdU+BrdU+ cells (CCH1, CCH5, CCH2 and NCH6 cells), at indicated time points, are shown. G.Timings of S-phase exit (red) for all cells were calculated using linear regression.
Supplementary Fig. S1 from Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells
Authors: Ko Jen-Chung , Hong Jhao-Hao , Wang Lyu-Han , Cheng Chau-Ming , Ciou Shih-Ci , Lin Szu-Ting , Jheng Ming-Yan , Lin Yun-Wei
Published: April 2023

Supplementary Fig. S1 from Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells
Supplementary Fig. S1 from Anticancer effects of tanshinone I in human non-small cell lung cancer
Authors: Lee Chen-Yu , Sher Hui-Fang , Chen Huei-Wen , Liu Chun-Chi , Chen Ching-Hsien , Lin Choun-Sea , Yang Pan-Chyr , Tsay Hsin-Sheng , Chen Jeremy J.W.
Published: April 2023

Supplementary Fig. S1 from Anticancer effects of tanshinone I in human non-small cell lung cancer
Supplementary Fig. S3 from Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes
Authors: Lang Sven A. , Schachtschneider Philipp , Moser Christian , Mori Akira , Hackl Christina , Gaumann Andreas , Batt David , Schlitt Hans J. , Geissler Edward K. , Stoeltzing Oliver
Published: April 2023

Supplementary Fig. S3 from Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes
Supplementary Fig. S1 from Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes
Authors: Lang Sven A. , Schachtschneider Philipp , Moser Christian , Mori Akira , Hackl Christina , Gaumann Andreas , Batt David , Schlitt Hans J. , Geissler Edward K. , Stoeltzing Oliver
Published: April 2023

Supplementary Fig. S1 from Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes
Supplementary Fig. S1 from PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
Authors: Carpinelli Patrizia , Ceruti Roberta , Giorgini Maria Laura , Cappella Paolo , Gianellini Laura , Croci Valter , Degrassi Anna , Texido Gemma , Rocchetti Maurizio , Vianello Paola , Rusconi Luisa , Storici Paola , Zugnoni Paola , Arrigoni Claudio , Soncini Chiara , Alli Cristina , Patton Veronica , Marsiglio Aurelio , Ballinari Dario , Pesenti Enrico , Fancelli Daniele , Moll Jürgen
Published: April 2023

Supplementary Fig. S1 from PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
Supplementary Table S1 from Asparagine synthetase is a predictive biomarker of l-asparaginase activity in ovarian cancer cell lines
Authors: Lorenzi Philip L. , Llamas Jenny , Gunsior Michele , Ozbun Laurent , Reinhold William C. , Varma Sudhir , Ji Helen , Kim Hijoo , Hutchinson Amy A. , Kohn Elise C. , Goldsmith Paul K. , Birrer Michael J. , Weinstein John N.
Published: April 2023

Supplementary Table S1 from Asparagine synthetase is a predictive biomarker of l-asparaginase activity in ovarian cancer cell lines
Supplementary Figure 3 from Chemopreventive and Chemotherapeutic Effects of Intravesical Silibinin against Bladder Cancer by Acting on Mitochondria
Authors: Zeng Jin , Sun Yi , Wu Kaijie , Li Lei , Zhang Gang , Yang Zenglei , Wang Zhiqiang , Zhang Dong , Xue Yan , Chen Yule , Zhu Guodong , Wang Xinyang , He Dalin
Published: April 2023

Supplementary Figure 3 from Chemopreventive and Chemotherapeutic Effects of Intravesical Silibinin against Bladder Cancer by Acting on Mitochondria
Supplementary Figure Legend for Supplementary Figure 1 from Silencing of Tubulin Binding Cofactor C Modifies Microtubule Dynamics and Cell Cycle Distribution and Enhances Sensitivity to Gemcitabine in Breast Cancer Cells
Authors: Hage-Sleiman Rouba , Herveau Stéphanie , Matera Eva-Laure , Laurier Jean-Fabien , Dumontet Charles
Published: April 2023

Supplementary Figure Legend for Supplementary Figure 1 from Silencing of Tubulin Binding Cofactor C Modifies Microtubule Dynamics and Cell Cycle Distribution and Enhances Sensitivity to Gemcitabine in Breast Cancer Cells
Supplementary Figure 1 from Modulation of drug resistance by artificial transcription factors
Authors: Blancafort Pilar , Tschan Mario P. , Bergquist Sharon , Guthy Daniel , Brachat Arndt , Sheeter Dennis A. , Torbett Bruce E. , Erdmann Dirk , Barbas Carlos F.
Published: April 2023

Supplementary Figure 1 from Modulation of drug resistance by artificial transcription factors
Supplementary Fig. S2 from Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism
Authors: Payré Bruno , de Medina Philippe , Boubekeur Nadia , Mhamdi Loubna , Bertrand-Michel Justine , Tercé François , Fourquaux Isabelle , Goudounèche Dominique , Record Michel , Poirot Marc , Silvente-Poirot Sandrine
Published: April 2023

Supplementary Fig. S2 from Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism
Supplementary Fig. S1 from Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism
Authors: Payré Bruno , de Medina Philippe , Boubekeur Nadia , Mhamdi Loubna , Bertrand-Michel Justine , Tercé François , Fourquaux Isabelle , Goudounèche Dominique , Record Michel , Poirot Marc , Silvente-Poirot Sandrine
Published: April 2023

Supplementary Fig. S1 from Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism
Supplementary Fig from Proteomic characterization of cytoskeletal and mitochondrial class III β-tubulin
Authors: Cicchillitti Lucia , Penci Roberta , Di Michele Michela , Filippetti Flavia , Rotilio Domenico , Donati Maria Benedetta , Scambia Giovanni , Ferlini Cristiano
Published: April 2023

Supplementary Fig from Proteomic characterization of cytoskeletal and mitochondrial class III β-tubulin
Supplementary Figures 1-5 from Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma
Authors: Nagai Tomoyuki , Arao Tokuzo , Furuta Kazuyuki , Sakai Kazuko , Kudo Kanae , Kaneda Hiroyasu , Tamura Daisuke , Aomatsu Keiichi , Kimura Hideharu , Fujita Yoshihiko , Matsumoto Kazuko , Saijo Nagahiro , Kudo Masatoshi , Nishio Kazuto
Published: April 2023

Supplementary Figures 1-5 from Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma
Supplementary Figure Legends from Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma
Authors: Nagai Tomoyuki , Arao Tokuzo , Furuta Kazuyuki , Sakai Kazuko , Kudo Kanae , Kaneda Hiroyasu , Tamura Daisuke , Aomatsu Keiichi , Kimura Hideharu , Fujita Yoshihiko , Matsumoto Kazuko , Saijo Nagahiro , Kudo Masatoshi , Nishio Kazuto
Published: April 2023

Supplementary Figure Legends from Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma
Supplementary Fig. S2 from Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
Authors: Gonzales Andrea J. , Hook Kenneth E. , Althaus Irene W. , Ellis Paul A. , Trachet Erin , Delaney Amy M. , Harvey Patricia J. , Ellis Teresa A. , Amato Danielle M. , Nelson James M. , Fry David W. , Zhu Tong , Loi Cho-Ming , Fakhoury Stephen A. , Schlosser Kevin M. , Sexton Karen E. , Winters R. Thomas , Reed Jessica E. , Bridges Alex J. , Lettiere Daniel J. , Baker Deborah A. , Yang Jianxin , Lee Helen T. , Tecle Haile , Vincent Patrick W.
Published: April 2023

Supplementary Fig. S2 from Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
Supplementary Fig. S1 from Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy
Authors: Su David M. , Zhang Qiuyang , Wang Xuexi , He Ping , Zhu Yuelin Jack , Zhao Jianxiong , Rennert Owen M. , Su Yan A.
Published: April 2023

Supplementary Fig. S1 from Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy
Supplementary Fig. S1 from The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model
Authors: VanderPorten Erica C. , Taverna Pietro , Hogan Jennifer N. , Ballinger Marcus D. , Flanagan W. Michael , Fucini Raymond V.
Published: April 2023

Supplementary Fig. S1 from The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model
Supplementary Fig. S2 from Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor
Authors: Abouantoun Thamara J. , MacDonald Tobey J.
Published: April 2023

Supplementary Fig. S2 from Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor
Supplementary Table S2 from Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901
Authors: Leyton Julius , Smith Graham , Lees Mark , Perumal Meg , Nguyen Quang-de , Aigbirhio Franklin I. , Golovko Oksana , He Quimin , Workman Paul , Aboagye Eric O.
Published: April 2023

Supplementary Table S2 from Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901
Supplementary Table S1 from Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901
Authors: Leyton Julius , Smith Graham , Lees Mark , Perumal Meg , Nguyen Quang-de , Aigbirhio Franklin I. , Golovko Oksana , He Quimin , Workman Paul , Aboagye Eric O.
Published: April 2023

Supplementary Table S1 from Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901
Supplementary Data from Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo
Authors: Tardi Paul G. , Dos Santos Nancy , Harasym Troy O. , Johnstone Sharon A. , Zisman Natalia , Tsang Alan W. , Bermudes David G. , Mayer Lawrence D.
Published: April 2023

Supplementary Data from Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo
Supplementary Figure 3C-3F from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Authors: Weisberg Ellen , Choi Hwan Geun , Barrett Rosemary , Zhou Wenjun , Zhang Jianming , Ray Arghya , Nelson Erik A. , Jiang Jingrui , Moreno Daisy , Stone Richard , Galinsky Ilene , Fox Edward , Adamia Sophia , Kung Andrew L. , Gray Nathanael S. , Griffin James D.
Published: April 2023

Supplementary Figure 3C-3F from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Supplementary Tables A-M from Drugs aimed at targeting characteristic karyotypic phenotypes of cancer cells
Authors: Wallqvist Anders , Huang Ruili , Covell David G. , Roschke Anna V. , Gelhaus Kristen S. , Kirsch Ilan R.
Published: April 2023

Supplementary Tables A-M from Drugs aimed at targeting characteristic karyotypic phenotypes of cancer cells
Video--pre- PEGPH20 tumor vascular area from Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models
Authors: Thompson Curtis B. , Shepard H. Michael , O'Connor Patrick M. , Kadhim Salam , Jiang Ping , Osgood Ryan J. , Bookbinder Louis H. , Li Xiaoming , Sugarman Barry J. , Connor Robert J. , Nadjsombati Sinisa , Frost Gregory I.
Published: April 2023

Video - 2-D ultrasound cine loop of pre- PEGPH20 tumor vascular area 15 mg/kg PEGPH20 at t = 0; Mouse #149
Supplementary Fig. S1 from In vivo silencing of a molecular target by short interfering RNA electroporation: tumor vascularization correlates to delivery efficiency
Authors: Takei Yoshifumi , Nemoto Toshio , Mu Ping , Fujishima Tatsuya , Ishimoto Takuji , Hayakawa Yasuhiko , Yuzawa Yukio , Matsuo Seiichi , Muramatsu Takashi , Kadomatsu Kenji
Published: April 2023

Supplementary Fig. S1 from In vivo silencing of a molecular target by short interfering RNA electroporation: tumor vascularization correlates to delivery efficiency
Supplementary Fig. S1 from Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib
Authors: Luster Troy A. , Carrell Jeffrey A. , McCormick Kathy , Sun David , Humphreys Robin
Published: April 2023

Supplementary Fig. S1 from Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib
Supplementary Data from Inhibition of the Insulin-Like Growth Factor I Receptor by Epigallocatechin Gallate Blocks Proliferation and Induces the Death of Ewing Tumor Cells
Authors: Kang Hyung-Gyoo , Jenabi Jasmine M. , Liu Xian Fang , Reynolds C. Patrick , Triche Timothy J. , Sorensen Poul H.B.
Published: April 2023

Supplementary Data from Inhibition of the Insulin-Like Growth Factor I Receptor by Epigallocatechin Gallate Blocks Proliferation and Induces the Death of Ewing Tumor Cells
Supplementary Table 1 from Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells
Authors: Sun Feng , Chan Eli , Wu Zhenlong , Yang Xiaojing , Marquez Victor E. , Yu Qiang
Published: April 2023

Supplementary Table 1 from Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells
Supplementary Figure Legends from Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen
Authors: Ariazi Eric A. , Leitão Andrei , Oprea Tudor I. , Chen Bin , Louis Teresa , Bertucci Anne Marie , Sharma Catherine G.N. , Gill Shaun D. , Kim Helen R. , Shupp Heather A. , Pyle Jennifer R. , Madrack Alexis , Donato Anne L. , Cheng Dong , Paige James R. , Jordan V. Craig
Published: April 2023

Supplementary Figure Legends from Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen
Supplementary Fig. S1 from Radiosensitization of solid tumors by Z-VAD, a pan-caspase inhibitor
Authors: Moretti Luigi , Kim Kwang Woon , Jung Dae Kwang , Willey Christopher D. , Lu Bo
Published: April 2023

Supplementary Fig. S1 from Radiosensitization of solid tumors by Z-VAD, a pan-caspase inhibitor
Supplementary Table S2 from Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid
Authors: Domhan Sophie , Muschal Stefan , Schwager Christian , Morath Christian , Wirkner Ute , Ansorge Wilhelm , Maercker Christian , Zeier Martin , Huber Peter E. , Abdollahi Amir
Published: April 2023

Supplementary Table S2 from Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid
Supplementary Table S2 from AMG 479, a fully human anti–insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells
Authors: Beltran Pedro J. , Mitchell Petia , Chung Young-A , Cajulis Elaina , Lu John , Belmontes Brian , Ho Joanne , Tsai Mei Mei , Zhu Min , Vonderfecht Steven , Baserga Renato , Kendall Richard , Radinsky Robert , Calzone Frank J.
Published: April 2023

Supplementary Table S2 from AMG 479, a fully human anti–insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells